Retreatment With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5

ASH 2020: Study examined outcomes of patients with relapsed indolent lymphoma retreated with CAR T-cell therapy Axicabtagene Ciloleucel.